Lutropin Alfa
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Lutropin Alfa
- Lutropin alfa: From Infertility Treatment to Postural Orthostatic Tachycardia Syndrome
Lutropin alfa: From Infertility Treatment to Postural Orthostatic Tachycardia Syndrome
One-Sentence Summary
Lutropin alfa is a recombinant human luteinizing hormone (LH) used in fertility treatment. In Singapore it is marketed alone (Luveris) and in combination with follitropin alfa (Pergoveris). The TxGNN model predicts it may be effective for postural orthostatic tachycardia syndrome, but there are currently 0 clinical trials and 0 publications supporting this direction. The prediction rests on the computational score alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not stated in the Singapore licence records compiled for this report (the drug is known as a recombinant LH acting on gonadal LH/choriogonadotropin receptors) |
| Predicted New Indication | Postural orthostatic tachycardia syndrome |
| TxGNN Prediction Score | 97.04% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 5 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the data compiled for this report. Based on known pharmacology, lutropin alfa is a recombinant human LH that acts on LH/choriogonadotropin receptors in gonadal tissue. Its established role is in ovarian stimulation, not cardiovascular or autonomic regulation.
No established mechanistic link to postural orthostatic tachycardia syndrome (POTS) has been identified. The high TxGNN score (97.04%) is a knowledge-graph prediction only, and the model's rank for this pair (21,133) is not strong. Because the mechanism of action data is missing, no pathway-level rationale can be assessed.
The other top-ranked predictions are similarly unsupported: peptic esophagitis (97.02%), trichotillomania (96.31%), Raynaud disease (95.65%), duodenal ulcer (95.58%), Tourette syndrome (95.18%), esophageal disease, sinoatrial block, multiple endocrine neoplasia and duodenogastric reflux. None has trials or literature, and no biologically plausible link to LH receptor agonism. The scores likely reflect proximity in the knowledge graph rather than biology.
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN12507P | Luveris for Injection 75 iu/vial (Revised formula) | Injection, powder, for solution | Not available |
| SIN15713P | Pergoveris Solution for Injection in Pre-filled Pen (900 IU + 450 IU)/1.44 mL | Injection, solution | Not available |
| SIN15711P | Pergoveris Solution for Injection in Pre-filled Pen (300 IU + 150 IU)/0.48 mL | Injection, solution | Not available |
| SIN15712P | Pergoveris Solution for Injection in Pre-filled Pen (450 IU + 225 IU)/0.72 mL | Injection, solution | Not available |
| SIN13990P | Pergoveris Powder and Solvent for Solution for Injection 150iu/75iu | Injection, powder, for solution | Not available |
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is supported only by a model score, with no clinical trials, no literature and no plausible mechanistic link between LH receptor agonism and POTS. Evidence is at the lowest level (L5), and safety data are incomplete.
To proceed, the following is needed:
- Package insert warnings and contraindications from the Singapore regulator (HSA), required before any safety screening
- Mechanism of action data for lutropin alfa
- Approved indication text for the Singapore licences
- Any preclinical or clinical evidence linking LH signalling to POTS or the other predicted conditions
- Assessment of route compatibility and of the rationale for a new patient population, since the product is currently used in fertility treatment
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.